Correction to: Elagolix: First Global Approval

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1179-1950
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Correction to: Elagolix: First Global Approval ; volume:78 ; number:17 ; day:15 ; month:11 ; year:2018 ; pages:1855 ; date:11.2018
Drugs ; 78, Heft 17 (15.11.2018), 1855, 11.2018

Urheber
Lamb, Yvette N.
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s40265-018-1014-3
URN
urn:nbn:de:101:1-2019011319335125389401
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:47 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Lamb, Yvette N.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Correction to: Fremanezumab: First Global Approval

Correction to: Fremanezumab: First Global Approval

Correction to: Ivosidenib: First Global Approval

Correction to: Ivosidenib: First Global Approval

Correction to: Sarecycline: First Global Approval

Correction to: Sarecycline: First Global Approval

Correction to: Revefenacin: First Global Approval

Correction to: Revefenacin: First Global Approval

Correction to: Caplacizumab: First Global Approval

Correction to: Caplacizumab: First Global Approval

Correction to: Delafloxacin: First Global Approval

Correction to: Delafloxacin: First Global Approval

Correction to: Ibalizumab: First Global Approval

Correction to: Ibalizumab: First Global Approval

Correction to: Moxetumomab Pasudotox: First Global Approval

Correction to: Moxetumomab Pasudotox: First Global Approval

Correction to: Polatuzumab Vedotin: First Global Approval

Correction to: Polatuzumab Vedotin: First Global Approval

Correction to: Andexanet Alfa: First Global Approval

Correction to: Andexanet Alfa: First Global Approval

Correction to: Lonafarnib: First Approval

Correction to: Lonafarnib: First Approval

Correction to: Pexidartinib: First Approval

Correction to: Pexidartinib: First Approval

Verbundene Objekte